Hemab Therapeutics Announces First Patient Dosed in Phase 2

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia

Hemab Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Investigating HMB-001 for the Treatment of Glanzmann Thrombasthenia

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , United Kingdom , Copenhagen , Køavn , Denmark , Cambridge , Cambridgeshire , Benny Sorensen , Viia Fviia , Glanzmann Thrombasthenia , American Society Of Hematology Annual Meeting , Drug Administration , Investigational New Drug , Fast Track Designation , Fast Track , American Society , Hematology Annual Meeting , Bernard Soulier Syndrome , Von Willebrand Disease ,